Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q4 2025 (December 31)8holders
0new positions
1sold out
$13.30avg. 13F price*
At the end of Q4 2025, 8 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were Hantz Financial Services, Inc. ($2.9M), Lanark Financial, Inc. ($686K) and Rhumbline Advisers ($311K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $3K |
All 13F filers, Q3 2025 → Q4 2025: 2,165 shares bought and 15,279 shares sold, net −13,114 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Hantz Financial Services, Inc. | 0.04% | Reduce -3.5% | 217,432 | $2.9M |
| Lanark Financial, Inc. | 0.05% | Reduce -10.0% | 51,360 | $686K |
| Rhumbline Advisers | 0.00% | Reduce -5.8% | 23,408 | $311K |
| GAMMA Investing LLC | 0.01% | Add +24.0% | 10,840 | $144K |
| Wellington-Altus USA Inc. | 0.01% | — | 1,486 | $20K |
| Salomon & Ludwin, LLC | 0.00% | Reduce -10.2% | 734 | $10K |
| Wealth Preservation Advisors, LLC | 0.00% | Add +29.0% | 289 | $4K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 56 | $744 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.